Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352(9137): 1331–6 ArticlePubMedCAS Google Scholar
Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995; 5(3): 239–44 ArticlePubMedCAS Google Scholar
Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol 1998; 13Suppl. 2: S115–23 Article Google Scholar
Cumming RG, Klineberg RJ. Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 1993; 158: 414–7 PubMedCAS Google Scholar
Herings RMC, Stricker BH, De Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures: dosage more mportant than half-life. Arch Intern Med 1995; 155: 1801–7 ArticlePubMedCAS Google Scholar
Lichtenstein MJ, Griffin MR, Cornell JE, et al. Risk factors for hip fractures occurring in the hospital. Am J Epidemiol 1994; 140(9): 830–8 PubMedCAS Google Scholar
Neutel CI, Downey W, Senet D. Medical events after a prescription for a benzodiazepine. Pharmacoepidemiol Drug Saf 1995; 4: 63–73 Article Google Scholar
Maxwell CJ, Neutel CI, Hirdes JP. A prospective study of falls after benzodiazepine use: a comparison between new and repeat use. Pharmacoepidemiol Drug Saf 1997; 6: 27–35 ArticlePubMedCAS Google Scholar
Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–9 ArticlePubMedCAS Google Scholar
Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303–7 ArticlePubMedCAS Google Scholar
ICADTS. Guidelines on experimental studies undertaken to determine a medicinal drug’s effect on driving or skills related to driving. Koeln: Bundes Anstalt fuer Strassenwesen (BASt), 1999 Jun Google Scholar
Vermeeren A, De Gier JJ, O’Hanlon JF. Methodological guidelines for experimental research on medicinal drugs affecting riving performance: an international expert survey. Maastricht: Institute for Human Psychopharmacology, 1993. Report No.: IHP 93-127 Google Scholar
Wolschrijn H, De Gier JJ, De Smet PAGM. Drugs and driving new categorization system for medicinal drugs. Maastricht: Institute for Drugs, Safety and Behavior, 1991. Report No.: IGVG 91-124
Berghaus G. Arzneimittel und Fahrtuechtigkeit: Metaanalyse experimenteller Studien. Bergisch Gladbach: Bundesanstalt fuer Strassenwesen, 1998. Report No.: FP 2.9108
O’Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982; 217(4554): 79–81 ArticlePubMed Google Scholar
O’Hanlon JF. Driving performance under the influence of drugs: rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18Suppl. 1: 121s–9 ArticlePubMed Google Scholar
Patat A, Paty I, Hindmarch I. Pharmacodynamic profile of zaleplon, a new non-benzodiazepine hypnotic agent. Hum Psychopharmacol 2001; 16(5): 369–92 ArticlePubMedCAS Google Scholar
Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as a hypnotic [update of 1986]. Drugs 1991; 32: 48–65 Article Google Scholar
O’Hanlon JF. Zopiclone’s residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: a critical review. Eur Psychiatry 1995; 10Suppl. 3: 137s–43 ArticlePubMed Google Scholar
Nicholson AN. Residual sequelae of zopiclone. Rev Contemp Pharmacother 1998; 9(2): 123–9 CAS Google Scholar
Noble S, Langtry HD, Lamb HM. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55(2): 277–302 ArticlePubMedCAS Google Scholar
Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40(2): 291–313 ArticlePubMedCAS Google Scholar
Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998; 61(3): 253–69 ArticlePubMedCAS Google Scholar
Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology 1982; 76: 101–13 ArticlePubMedCAS Google Scholar
Roth T, Roehrs T. Determinants of residual effects of hypnotics. Accid Anal Prev 1985; 17(4): 291–6 ArticlePubMedCAS Google Scholar
Roth T, Roehrs TA. A review of the safety profiles of benzodiazepinehypnotics. J Clin Psychiatry 1991; 52 Suppl.: 38–41 PubMed Google Scholar
Van Laar MW, Volkerts ER. Driving and benzodiazepine use:evidence that they do not mix. CNS Drugs 1998; 10(5):383–96 Article Google Scholar
Leger D, Guilleminault C, Dreyfus JP, et al. Prevalence ofnsomnia in a survey of 12,778 adults in France. J Sleep Res 2000; 9(1): 35–42 ArticlePubMedCAS Google Scholar
Baiter MB, Manheimer DI, Mellinger GD, et al. A cross-nationalcomparison of anti-anxiety/sedative drug use. Curr Med Res Opin 1984; 8 Suppl. 4: 5–20 Google Scholar
Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and itstreatment: prevalence and correlates. Arch Gen Psychiatry 1985; 42(3): 225–32 ArticlePubMedCAS Google Scholar
Pallesen S, Nordhus IH, Nielsen GH, et al. Prevalence ofinsomnia in the adult Norwegian population. Sleep 2001; 24(7): 771–9 PubMedCAS Google Scholar
Simon GE, VonKorff M. Prevalence, burden, and treatment ofinsomnia in primary care. Am J Psychiatry 1997; 154(10):1417–23 PubMedCAS Google Scholar
Ohayon MM, Roth T. What are the contributing factors forinsomnia in the general population? J Psychosom Res 2001; 51(6): 745–55 ArticlePubMedCAS Google Scholar
Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999; 22Suppl. 2: S347–53 PubMed Google Scholar
Christer GM, Hublin CGM, Partinen MM. The extent andimpact of insomnia as a public health problem. Primary Care Companion J Clin Psychiatry 2002; 4 Suppl. 1: 8–12 Google Scholar
Reite MD. Treatment of insomnia. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. 2nd ed. Washington,DC: American Psychiatric Press Inc., 1998: 997–1014 Google Scholar
Benca RM. Consequences of insomnia and its therapies. J Clin Psychiatry 2001; 62 Suppl. 10: 33–8 Google Scholar
Bond AJ, Lader MH. Residual effects of hypnotics. Psychopharmacology 1972; 25(2): 117–32 ArticleCAS Google Scholar
Bond AJ, Lader MH. The residual effects of flurazepam.Psychopharmacology 1973; 32(3): 223–35 ArticleCAS Google Scholar
Bond AJ, Lader MH. Residual effects of flunitrazepam. Br J Clin Pharmacol 1975; 2(2): 143–50 ArticlePubMedCAS Google Scholar
Borland RG, Nicholson AN. Comparison of the residual effects of two benzodiazepines (nitrazepam and flurazepam hydrochloride) and pentobarbitone sodium on human performance. Br J Clin Pharmacol 1975; 2(1): 9–17 PubMedCAS Google Scholar
Hindmarch I. A repeated dose comparison of three benzodiazepine derivative (nitrazepam, flurazepam and flunitrazepam) on subjective appraisals of sleep and measures of psychomotor performance the morning following night-time medication.Acta Psychiatr Scand 1977; 56(5): 373–81 ArticlePubMedCAS Google Scholar
Hindmarch I. Effects of hypnotic and sleep-inducing drugs on objective assessments of human psychomotor performanceand subjective appraisals of sleep and early morning behaviour.Br J Clin Pharmacol 1979; 8(1): 43s–6s ArticlePubMedCAS Google Scholar
Hindmarch I, Clyde CA. The effects of triazolam and nitrazepamon sleep quality, morning vigilance and psychomotorperformance. Arzneimittel Forschung 1980; 30(7): 1163–6 PubMedCAS Google Scholar
Aranko K, Mattila MJ, Seppala T. Development of toleranceand cross-tolerance to the psychomotor actions of lorazepamand diazepam in man. Br J Clin Pharmacol 1983; 15(5):545–52 ArticlePubMedCAS Google Scholar
Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: acritical review. J Clin Psychopharmacol 1989; 9(3): 161–72 ArticlePubMedCAS Google Scholar
Kales A, Soldatos CR, Bixler EO, et al. Rebound insomnia andrebound anxiety: a review. Pharmacology 1983; 26(3): 121–37 ArticlePubMedCAS Google Scholar
Lapeyre-Mestre M, Chastan E, Louis A, et al. Drug consumptionin workers in France: a comparative study at a 10-yearinterval (1996 versus 1986). J Clin Epidemiol 1999; 52(5):471–8 ArticlePubMedCAS Google Scholar
Walsh JK, Schweitzer PK. Ten-year trends in the pharmacologicaltreatment of insomnia. Sleep 1999; 22(3): 371–5 PubMedCAS Google Scholar
Doghramji K. The need for flexibility in dosing of hypnoticagents. Sleep 2000; 23Suppl. 1: s16–20 PubMed Google Scholar
Kirkwood CK. Management of insomnia. J Am Pharm Assoc 1999; 39(5): 688–96 CAS Google Scholar
Ohayon MM, Caulet M. Insomnia and psychotropic drug consumption.Prog Neuropsychopharmacol Biol Psychiatry 1995;19(3): 421–31 ArticlePubMedCAS Google Scholar
Ohayon MM, Caulet M, Guilleminault C. How a general populationperceives its sleep and how this relates to the complaintof insomnia. Sleep 1997; 20(9): 715–23 PubMedCAS Google Scholar
Ohayon MM, Caulet M, Priest RG, et al. Psychotropic medicationconsumption patterns in the UK general population. J Clin Epidemiol 1998; 51(3): 273–83 ArticlePubMedCAS Google Scholar
Ohayon MM, Vecchierini MF. Daytime sleepiness and cognitiveimpairment in the elderly population. Arch Intern Med 2002; 162(2): 201–8 ArticlePubMed Google Scholar
Roehrs T, Hollebeek E, Drake C, et al. Substance use forinsomnia in Metropolitan Detroit. J Psychosom Res 2002; 53(1): 571–6 ArticlePubMed Google Scholar
Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study.Sleep 1991; 14(5): 392–8 PubMedCAS Google Scholar
Bader G, Ohayon MM. Insomnia in the general population ofSweden. J Sleep Res 2002; 11 Suppl. 1: 10–1 Google Scholar
Ohayon MM, Lader MH. Use of psychotropic medication in thegeneral population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002; 63(9): 817–25 ArticlePubMed Google Scholar
Nowell PD, Buysse DJ, Reynolds 3rd CF, et al. Clinical factorscontributing to the differential diagnosis of primary insomniaand insomnia related to mental disorders. Am J Psychiatry 1997; 154(10): 1412–6 PubMedCAS Google Scholar
Doble A. New insights into the mechanism of action of hypnotics.J Psychopharmacol 1999; 13(4 Suppl. 1): S11–20 PubMedCAS Google Scholar
Landolt H-P, Gillin JC. GABA-A1a receptors: involvement insleep regulation and potential of selective agonists in thetreatment of insomnia. CNS Drugs 2000; 13(3): 185–99 ArticleCAS Google Scholar
Moehler H, Fritschy JM, Rudolph U. A new benzodiazepinepharmacology. J Pharmacol Exp Ther 2002; 300(1): 2–8 Article Google Scholar
McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative butnot anxiolytic properties of benzodiazepines are mediated bythe GABA (A) receptor alphal subtype. Nat Neurosci 2000; 3(6): 587–92 ArticlePubMedCAS Google Scholar
Hardman JG, Limbird LE, Gilman A. Goodman and Gillman’s:the pharmacological basis of therapeutics. 10th ed. New York: MacMillan, 2001 Google Scholar
Neutel CI, Hirdes JP, Maxwell CJ. New evidence on benzodiazepineuse and falls: the time factor. Age Ageing 1996; 25: 273–8 ArticlePubMedCAS Google Scholar
Herings RMC. Geneesmiddelen als determinant van ongevallen.Utrecht: Universiteit Utrecht, Faculteit Farmacie, 1994
Passaro A, Volpato S, Romagnoni F, et al. Benzodiazepineswith different half-life and falling in a hospitalized population:The GIFA study. Gruppo Italiano di Farmacovigilanza nell’Anziano.J Clin Epidemiol 2000; 53(12): 1222–9 CAS Google Scholar
Pierfitte C, Macouillard G, Thicoipe M, et al. Benzodiazepinesand hip fractures in elderly people: case-control study. BMJ 2001; 322(7288): 704–8 ArticlePubMedCAS Google Scholar
Ray WA, Fought RL, Decker MD. Psychoactive drugs and therisk of injurious motor vehicle crashes in elderly drivers. Am JEpidemiol 1992; 136: 873–83 ArticleCAS Google Scholar
Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in olderpeople: a systematic review and meta-analysis: I. psychotropicdrugs. J Am Geriatr Soc 1999; 47(1): 30–9 CAS Google Scholar
Neutel CI, Perry S, Maxwell C. Medication use and risk of falls.Pharmacoepidemiol Drug Saf 2002; 11(2): 97–104 ArticlePubMed Google Scholar
De Gier JJ. Review of investigations of prevalence of illicitdrugs in road traffic in diffrent European countries. In: Group P, editor. Road traffic and drugs; 1999. Strasbourg: Council ofEurope, 1999: 13–60 Google Scholar
Longo MC, Hunter CE, Lokan RJ, et al. The prevalence ofalcohol, cannabinoids, benzodiazepines and stimulantsamongst injured drivers and their role in driver culpability: parti: the prevalence of drug use in drive the drug-positive group.Accid Anal Prev 2000; 32(5): 613–22 ArticlePubMedCAS Google Scholar
Longo MC, Hunter CE, Lokan RJ, et al. The prevalence ofalcohol, cannabinoids, benzodiazepines and stimulantsamongst injured drivers and their role in driver culpability: partII: the relationship between drug prevalence and drug concentration,and driver culpability. Accid Anal Prev 2000; 32(5):623–32 ArticlePubMedCAS Google Scholar
Honkanen R, Ertama L, Linnoila M, et al. Role of drugs intraffic accidents. BMJ 1980; 281: 1309–12 ArticlePubMedCAS Google Scholar
Skegg DCG, Richards SM, Doll R. Minor tranquilisers and roadaccidents. BMJ 1979; 1(6168): 917–9 ArticlePubMedCAS Google Scholar
Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine useand the risk of motor vehicle crash in the elderly. JAMA 1997;278(1): 27–31 ArticlePubMedCAS Google Scholar
Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactivemedications and injurious motor vehicle collisions involvingolder drivers. Epidemiology 1994; 5(6): 591–8 ArticlePubMedCAS Google Scholar
Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects ofevening and middle-of-the-night administration of zaleplon 10and 20mg on memory and actual driving performance. Hum Psychopharmacol 1998; 13 Suppl. 2: S98–107 ArticleCAS Google Scholar
Vermeeren A, Riedel WJ, Van Boxtel CJ, et al. Differentialresidual effects of zaleplon and zopiclone on actual driving: acomparison with a low dose of alcohol. Sleep 2002; 25(2):224–31 PubMed Google Scholar
Volkerts ER, O’Hanlon JF. Residu effecten op de actuele rijprestatie:zopiclone versus flunitrazepam en nitrazepam (Residualeffects on real car driving performance: zopiclone versus flunitrazepamand nitrazepam; Dutch with English summary andlegends). J Drug Ther Res 1988; 13: 111–4 Google Scholar
Bramness JG, Skurtveit S, Morland J. Zopiklonfunn hos mangebilforere-tegn pa feilbruk og misbruk. Tidsskr Nor Laegeforen 1999; 119(19): 2820–1 PubMedCAS Google Scholar
Cumming RG, Le Couteur DG. Benzodiazepines and risk of hipfractures in older people: a review of the evidence. CNS Drugs 2003; 17: 825–37 ArticlePubMedCAS Google Scholar
Tromp AM, Pluijm SM, Smit JH, et al. Fall-risk screening test:a prospective study on predictors for falls in community-dwellingelderly. J Clin Epidemiol 2001; 54(8): 837–44 ArticlePubMedCAS Google Scholar
Ray WA, Thapa PB, Gideon P. Benzodiazepines and the risk offalls in nursing home residents. J Am Geriatr Soc 2000; 48(6):682–5 PubMedCAS Google Scholar
Ray WA, Thapa PB, Gideon P. Misclassification of currentbenzodiazepine exposure by use of single baseline measurementand its effects upon studies of injuries.Pharmacoepidemiol Drug Saf 2002; 11(11): 1–7 Google Scholar
Mendelson WB. The use of sedative/hypnotic medication andits correlation with falling down in the hospital. Sleep 1996; 19(9): 698–701 PubMedCAS Google Scholar
Lord SR, Anstey KJ, Williams P, et al. Psychoactive medicationuse, sensori-motor function and falls in older women.Br J Clin Pharmacol 1995; 39(3): 227–34 ArticlePubMedCAS Google Scholar
Cumming RG, Miller JP, Kelsey JL, et al. Medications andmultiple falls in elderly people: the St Louis OASIS Study.Age Ageing 1991; 20: 455–61 ArticlePubMedCAS Google Scholar
Campbell AJ, Borrie MJ, Spears GF. Risk factors for falls in acommunity-based prospective study of people 70 years andolder. J Gerontol A Biol Sci Med Sci 1989; 44(4): 112–7 Google Scholar
Granek E, Baker SP, Abbey H, et al. Medications and diagnosesin relation to falls in a long-term care facility. J Am Geriatr Soc 1987; 35(6): 503–11 PubMedCAS Google Scholar
Wang PS, Bohn RL, Glynn RJ, et al. Zolpidem use and hipfractures in older people. J Am Geriatr Soc 2001; 49(12):1685–90 ArticlePubMedCAS Google Scholar
Sgadari A, Lapane KL, Mor V, et al. Oxidative and nonoxidative benzodiazepines and the risk of femur fracture: the Systematic Assessment of Geriatric Drug Use Via Epidemiology Study Group. J Clin Psychopharmacol 2000; 20(2): 234–9 ArticlePubMedCAS Google Scholar
Blake AJ, Morgan K, Bendall MJ, et al. Falls by elderly peopleat home: prevalence and associated factors. Age Ageing 1988;17(6): 365–72 ArticlePubMedCAS Google Scholar
Riedel WJ, Vermeeren A, Van Boxtel MPJ, et al. Mechanismsof drug-induced driving impairment: a dimensional approach.Hum Psychopharmacol 1998; 13Suppl. 2: S49–63 ArticleCAS Google Scholar
O’Hanlon JF, Ramaekers JG. Antihistamine effects on actualdriving performance in a standard test: a summary of Dutchexperience, 1989–94. Allergy 1995; 50(3): 234–42 ArticlePubMed Google Scholar
O’Hanlon JF, Vermeeren A, Uiterwijk MM, et al. Anxiolytics’effects on the actual driving performance of patients andhealthy volunteers in a standardized test: an integration ofthree studies. Neuropsychobiol 1995; 31(2): 81–8 Article Google Scholar
Louwerens JW, Gloerich ABM, De Vries G, et al. The relationshipbetween drivers’ blood alcohol concentration (BAC) andactual driving performance during high speed travel. In:Noordzij PC, Roszbach R, editors. International congress onalcohol, drugs and traffic safety, T86; 1987. Amsterdam: ExerptaMedica, 1987: 183–6 Google Scholar
Borkenstein RF. The role of the drinking driver in traffic accidents,the Grand Rapids study. 2nd ed. Blutalcohol 1974; 11Suppl. 1: 1–131 Google Scholar
Vermeeren A, O’Hanlon JF, Declerck AC, et al. Acute effectsof zolpidem and flunitrazepam on sleep, memory and drivingperformance, compared to those of partial sleep deprivationand placebo. Acta Ther 1995; 21: 47–64 Google Scholar
Verster JC, Volkerts ER, Schreuder AH, et al. Residual effectsof middle-of-the-night administration of zaleplon and zolpidemon driving ability, memory functions, and psychomotorperformance. J Clin Psychopharmacol 2002; 22: 576–83 ArticlePubMedCAS Google Scholar
O’Hanlon JF, Volkerts ER. Hypnotics and actual driving performance.Acta Psychiatr Scand Suppl 1986; 332: 95–104 ArticlePubMed Google Scholar
Volkerts ER, Van Laar MW, Van Willigenburg AP, et al. Acomparative study of on-the-road and simulated driving performanceafter nocturnal treatment with lormetazepam 1mgand oxazepam 50mg. Hum Psychopharmacol 1992; 7(5):297–309 ArticleCAS Google Scholar
Brookhuis KA, Volkerts ER, O’Hanlon JF. Repeated dose effectsof lormetazepam and flurazepam upon driving performance.Eur J Clin Pharmacol 1990; 39(1): 83–7 ArticlePubMedCAS Google Scholar
Volkerts ER, O’Hanlon JF. Hypnotics’ residual effects on drivingperformance. In: O’Hanlon JF, De Gier JJ, editors. Drugsand driving. London: Taylor Francis, 1986 Google Scholar
O’Hanlon JF. Alcohol and hypnotic hangovers as an influenceon driving performance. Trav Traf Med Int 1983; 1(3): 147–52 Google Scholar
Vermeeren A, Ramaekers JG, Van Leeuwen CJ, et al. Residualeffects on actual car driving of evening dosing ofchlorpheniramine 8 and 12mg when use with terfenadine 60mgin the morning. Hum Psychopharmacol 1998; 13Suppl. 2:S79–86 ArticleCAS Google Scholar
Brookhuis KA, Volkerts ER, O’Hanlon JF. Repeated dose effectsof lormetazepam 1 and 2mg (in soft gelatine capsules)and flurazepam 30mg upon driving performance [Report VK86-18]. Haren: Traffic Research Centre, 1986. Report No.: VK86-18
Riedel WJ, Quasten R, Hausen C, et al. A study comparing thehypnotic efficacies and residual effects on actual driving performanceof midazolam 15mg, triazolam 0.5mg, temazepam20mg and placebo in shiftworkers on night duty. Technicalreport. Maastricht: Institute for Drugs Safety and Behavior,1988. Report No.: IGVG 88-01
Mclnnes GT, Bunting EA, Ings RM, et al. Pharmacokineticsand pharmacodynamics following single and repeated nightlyadministrations of loprazolam, a new benzodiazepine hypnotic.Br J Clin Pharmacol 1985; 19(5): 649–56 Article Google Scholar
Danjou P, Paty I, Fruncillo R, et al. A comparison of theresidual effects of zaleplon and zolpidem following administration5 to 2h before awakening. Br J Clin Pharmacol 1999; 48(3): 367–74 ArticlePubMedCAS Google Scholar
Hindmarch I, Patat A, Stanley N, et al. Residual effects ofzaleplon and zolpidem following middle of the night administrationfive hours to one hour before awakening. Hum Psychopharmacol 2001; 16: 159–67 ArticlePubMedCAS Google Scholar
Troy SM, Lucki I, Unruh MA, et al. Comparison of the effectsof zaleplon, zolpidem, and triazolam on memory, learning, andpsychomotor performance. J Clin Psychopharmacol 2000; 20(3): 328–37 ArticlePubMedCAS Google Scholar
Stone BM, Turner C, Mills SL, et al. Sleep in a noisy environment:hypnotic and residual effects of zaleplon [abstract]. JSleep Res 2000; 9 Suppl. 1: 183 Google Scholar
O’Hanlon JF. Residual effects on memory and psychomotorperformance of zaleplon and other hypnotic drugs. Prim CareCompanion J Clin Psychiatry 2002; 4 Suppl. 1: 38–44 Google Scholar
Darcourt G, Pringuey D, Salliere D, et al. The safety andtolerability of zolpidem: an update. J Psychopharmacol 1999;3(1): 81–93 Article Google Scholar
Lader M, Hindmarch I. Memory, psychomotor and cognitivefunctions after treatment with zolpidem. In: Freeman H, Puech AJ, Roth T, editors. Zolpidem: un update of its pharmacologicalproperties and therapeutic place in management of insomnia.Paris: Elsevier, 1996 Google Scholar
Unden M, Roth Schechter B. Next day effects after nighttimetreatment with zolpidem: a review. Eur Psychiatry 1996; 11Suppl. 1: S21–30 Article Google Scholar
Erman MK, Erwin CW, Gengo FM, et al. Comparative efficacyof zolpidem and temazepam in transient insomnia. Hum Psychopharmacol 2001; 16: 169–76 ArticlePubMedCAS Google Scholar
Zammit G. Zaleplon vs zolpidem: differences in next-dayresidual sedation after middle-of-the-night administration [abstract].J Sleep Res 2000; 9Suppl. 1: 214 Google Scholar
Cluydts R, De Roeck J, Schotte C, et al. Comparative study onthe residual daytime effects of flunitrazepam, triazolam, andplacebo in healthy volunteers. Acta Ther 1986; 12: 205–17 CAS Google Scholar
Mintzer MZ, Frey JM, Yingling JE, et al. Triazolam andzolpidem: a comparison of their psychomotor, cognitive, andsubjective effects in healthy volunteers. Behav Pharmacol1997; 8(6–7): 561–74 ArticlePubMedCAS Google Scholar
Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam:behavioral and subject-rated effects in normal volunteers. JClin Psychopharmacol 1996; 16(2): 146–57 ArticleCAS Google Scholar
Moskowitz H, Linnoila M, Roehrs T. Psychomotor performancein chronic insomniacs during 14-day use of flurazepam andmidazolam. J Clin Psychopharmacol 1990; 104Suppl. 4: 44s–55 Google Scholar
Jackson JL, Louwerens JW, Cnossen F, et al. Testing the effectsof hypnotics on memory via the telephone: fact or fiction? Psychopharmacology 1993; 111(2): 127–33 ArticlePubMedCAS Google Scholar
Godtlibsen OB, Jerko D, Gordeladze JO, et al. Residual effectof single and repeated doses of midazolam and nitrazepam inrelation to their plasma concentrations. Eur J Clin Pharmacol 1986; 29: 595–600 ArticleCAS Google Scholar
Borbely AA, Mattmann P, Loepfe M. Hypnotic action andresidual effects of a single bedtime dose of temazepam.Arzneimittel Forschung 1984; 34(1): 101–3 PubMedCAS Google Scholar
Hemmeter U, Muller M, Bischof R, et al. Effect of zopicloneand temazepam on sleep EEG parameters, psychomotor andmemory functions in healthy elderly volunteers. Psychopharmacology 2000; 147(4): 384–96 ArticlePubMedCAS Google Scholar
Hindmarch I. Hypnotics and residual sequalae. In: Nicholson AN, editor. Hypnotics in clinical practice. Edinburgh: MedicinePublishing Foundation, 1982: 7–16 Google Scholar
Porcu S, Bellatreccia A, Ferrara M, et al. Performance, abilityto stay awake, and tendency to fall asleep during the night aftera diurnal sleep with temazepam or placebo. Sleep 1997; 20(7):535–41 PubMedCAS Google Scholar
Warburton DM, Wesnes K. A comparison of temazepam andflurazepam in terms of sleep quality and residual changes inactivation and performance. Arzneimittel Forschung 1984; 34(11): 1601–4 PubMedCAS Google Scholar
Volkerts ER, Abbink F. Kater-effecten op de rijvaardigheid naslaapmiddelgebruik? Lormetazepam en oxazepam versus placebo(Hangover effects on driving performance following useof hypnotics?). J Drug Ther Res 1990; 15(1): 22–6 Google Scholar
Bourin M, Hubert C, Colombel MC, et al. Residual effects oftemazepam versus nitrazepam on memory and vigilance in thenormal subject. Hum Psychopharmacol 1987; 2: 185–9 ArticleCAS Google Scholar
Laurell H, Tornros J. The carry-over effects of triazolam comparedwith nitrazepam and placebo in acute emergency drivingsituations and in monotonous simulated driving. Acta Pharmacol Toxicol (Copenh) 1986; 58(3): 182–6 ArticleCAS Google Scholar
Morgan K. Effects of repeated dose nitrazepam andlormetazepam on psychomotor performance in the elderly.Psychopharmacology 1985; 86(1–2): 209–11 ArticlePubMedCAS Google Scholar
Subhan Z, Hindmarch I. Asessing residual effects of benzodiazepineson short term memory. Pharm Med 1984; 1: 27–32 CAS Google Scholar
Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 1997; 17(3 Suppl. 2): 1s–57 ArticlePubMedCAS Google Scholar
Carvey PM. Drug action in the central nervous system. NewYork: Oxford University Press, 1998 Google Scholar
Roehrs T, Kribbs N, Zorick F, et al. Hypnotic residual effects ofbenzodiazepines with repeated administration. Sleep 1986; 9(2): 309–16 PubMedCAS Google Scholar
Menzin J, Lang KM, Levy P, et al. A general model of theeffects of sleep medications on the risk and cost of motorvehicle accidents and its application to France. Pharmacoeconomics 2001; 19(1): 69–78 ArticlePubMedCAS Google Scholar